RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Astellas Pharma Stock

Astellas Pharma Revenue 2024

Astellas Pharma Revenue

1.6 T JPY

Ticker

4503.T

ISIN

JP3942400007

WKN

856273

In 2024, Astellas Pharma's sales reached 1.6 T JPY, a 5.6% difference from the 1.52 T JPY sales recorded in the previous year.

The Astellas Pharma Revenue history

YEARREVENUE (undefined JPY)GROSS MARGIN (%)
2027e1.9666,77
2026e1.8371,49
2025e1.7674,53
20241.681,76
20231.5281,01
20221.380,48
20211.2580,31
20201.378,73
20191.3177,64
20181.377,37
20171.3175,57
20161.3775,55
20151.2573,29
20141.1471,00
20131.0167,77
20120.9767,13
20110.9568,97
20100.9770,33
20090.9772,62
20080.9771,28
20070.9269,02
20060.8868,66
20050.4568,13

Astellas Pharma Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Astellas Pharma, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Astellas Pharma from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Astellas Pharma’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Astellas Pharma. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Astellas Pharma’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Astellas Pharma’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Astellas Pharma’s growth potential.

Astellas Pharma Revenue, EBIT and net profit per share

DateAstellas Pharma RevenueAstellas Pharma EBITAstellas Pharma Net Income
2027e1.96 T undefined477.92 B undefined215.95 B undefined
2026e1.83 T undefined441.88 B undefined149.8 B undefined
2025e1.76 T undefined328.76 B undefined56.96 B undefined
20241.6 T undefined124.61 B undefined17.05 B undefined
20231.52 T undefined231.65 B undefined98.71 B undefined
20221.3 T undefined218.15 B undefined124.09 B undefined
20211.25 T undefined250.93 B undefined120.59 B undefined
20201.3 T undefined267.48 B undefined195.41 B undefined
20191.31 T undefined288.23 B undefined222.27 B undefined
20181.3 T undefined277.69 B undefined164.68 B undefined
20171.31 T undefined273.81 B undefined218.7 B undefined
20161.37 T undefined267.18 B undefined193.69 B undefined
20151.25 T undefined210.64 B undefined135.86 B undefined
20141.14 T undefined187.83 B undefined90.87 B undefined
20131.01 T undefined153.87 B undefined82.85 B undefined
2012969.39 B undefined131.52 B undefined78.23 B undefined
2011953.95 B undefined119.18 B undefined67.65 B undefined
2010974.88 B undefined186.41 B undefined122.26 B undefined
2009965.7 B undefined250.4 B undefined170.99 B undefined
2008972.59 B undefined275.91 B undefined177.44 B undefined
2007920.62 B undefined189.39 B undefined131.29 B undefined
2006879.36 B undefined190.4 B undefined103.57 B undefined
2005447.05 B undefined96.1 B undefined33.67 B undefined

Astellas Pharma stock margins

The Astellas Pharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Astellas Pharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Astellas Pharma.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Astellas Pharma's sales revenue. A higher gross margin percentage indicates that the Astellas Pharma retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Astellas Pharma's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Astellas Pharma's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Astellas Pharma's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Astellas Pharma. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Astellas Pharma's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Astellas Pharma Margin History

Astellas Pharma Gross marginAstellas Pharma Profit marginAstellas Pharma EBIT marginAstellas Pharma Profit margin
2027e81.76 %24.34 %11 %
2026e81.76 %24.09 %8.17 %
2025e81.76 %18.69 %3.24 %
202481.76 %7.77 %1.06 %
202381.01 %15.25 %6.5 %
202280.48 %16.83 %9.57 %
202180.31 %20.08 %9.65 %
202078.73 %20.56 %15.02 %
201977.64 %22.06 %17.01 %
201877.37 %21.36 %12.66 %
201775.57 %20.88 %16.67 %
201675.55 %19.46 %14.11 %
201573.29 %16.89 %10.89 %
201471 %16.48 %7.97 %
201367.77 %15.3 %8.24 %
201267.13 %13.57 %8.07 %
201168.97 %12.49 %7.09 %
201070.33 %19.12 %12.54 %
200972.62 %25.93 %17.71 %
200871.28 %28.37 %18.24 %
200769.02 %20.57 %14.26 %
200668.66 %21.65 %11.78 %
200568.13 %21.5 %7.53 %

Astellas Pharma Aktienanalyse

What does Astellas Pharma do?

Astellas Pharma Inc. is a global pharmaceutical company based in Tokyo, Japan. The company manufactures and distributes medications worldwide. It was formed in April 2005 through the merger of two well-known Japanese pharmaceutical companies - Yamanouchi and Fujisawa. This merger created one of Japan's largest pharmaceutical companies and allowed for collaboration on the global market and the development of new innovations in medication research. Astellas' business model is focused on targeted research and development, comprehensive marketing and distribution networks, and collaboration with international partners. The company's main areas of focus are cancer, urology, transplantation, anti-infectives, and pneumology. Astellas has expanded its business through acquisitions and partnerships and currently operates in over 50 countries worldwide. In addition to pharmaceutical production, the company also provides services and consulting in the medical and health sectors. Astellas' business is divided into segments including pharmaceuticals, medical devices, and diagnostics. The pharmaceutical segment is the largest and offers a wide range of prescription medications for various medical areas. The medical devices segment specializes in the development and manufacturing of medical devices such as catheters, stents, and heart valves. The diagnostics segment focuses on developing and producing testing systems and instruments for diseases such as HIV and infectious diseases. Overall, Astellas is an important player in the global pharmaceutical and health industry, known for its innovative research, wide range of products, and collaboration with partners to develop campaigns against various diseases. Astellas Pharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Astellas Pharma's Sales Figures

The sales figures of Astellas Pharma originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Astellas Pharma’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Astellas Pharma's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Astellas Pharma’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Astellas Pharma stock

How much revenue did Astellas Pharma generate this year?

Astellas Pharma has achieved a revenue of 1.6 T JPY this year.

How much was the turnover of the company Astellas Pharma compared to the previous year?

The revenue of Astellas Pharma has increased by 5.6% increased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Astellas Pharma?

The revenue of Astellas Pharma is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Astellas Pharma measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Astellas Pharma so important for investors?

The revenue of Astellas Pharma is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Astellas Pharma pay?

Over the past 12 months, Astellas Pharma paid a dividend of 72 JPY . This corresponds to a dividend yield of about 4.18 %. For the coming 12 months, Astellas Pharma is expected to pay a dividend of 73.66 JPY.

What is the dividend yield of Astellas Pharma?

The current dividend yield of Astellas Pharma is 4.18 %.

When does Astellas Pharma pay dividends?

Astellas Pharma pays a quarterly dividend. This is distributed in the months of October, April, October, April.

How secure is the dividend of Astellas Pharma?

Astellas Pharma paid dividends every year for the past 23 years.

What is the dividend of Astellas Pharma?

For the upcoming 12 months, dividends amounting to 73.66 JPY are expected. This corresponds to a dividend yield of 4.28 %.

In which sector is Astellas Pharma located?

Astellas Pharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Astellas Pharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Astellas Pharma from 12/1/2024 amounting to 37 JPY, you needed to have the stock in your portfolio before the ex-date on 9/27/2024.

When did Astellas Pharma pay the last dividend?

The last dividend was paid out on 12/1/2024.

What was the dividend of Astellas Pharma in the year 2023?

In the year 2023, Astellas Pharma distributed 65 JPY as dividends.

In which currency does Astellas Pharma pay out the dividend?

The dividends of Astellas Pharma are distributed in JPY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Astellas Pharma stock can be added to a savings plan with the following providers: Consorsbank

Andere Kennzahlen von Astellas Pharma

Our stock analysis for Astellas Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Astellas Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.